Atara Biotherapeutics
Stock Forecast, Prediction & Price Target
Atara Biotherapeutics (ATRA) stock Price Target by analysts
$10
Potential downside: -16.66%
Atara Biotherapeutics price prediction
What is Atara Biotherapeutics stock analysts` prediction?
Atara Biotherapeutics stock forecast: Based on 1 Wall Street analysts` predicted price targets for Atara Biotherapeutics in the last 3 months, the avarage price target is $10, with a high forecast of $NaN. The average price target represents a -16.66% change from the last price of $12.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Atara Biotherapeutics stock Price Target by analysts
Full breakdown of analysts given Atara Biotherapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Benjamin Burnett Stifel Nicolaus | 0% 0/1 | 11 months ago | $10 -16.66% downside | $7.58 | StreetInsider | Previous targets (0) |
Salim Syed Mizuho Securities | 0% 0/1 | about 1 year ago | $18 50.00% upside | $6.83 | TheFly | Previous targets (0) |
Unknown Mizuho Securities | N/A | about 3 years ago | $31 158.33% upside | $5 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | about 3 years ago | $3 -74.99% downside | $3.87 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | over 3 years ago | $4 -66.66% downside | $4.85 | Benzinga | N/A |
Atara Biotherapeutics Financial Estimates
Atara Biotherapeutics Revenue Estimates
Atara Biotherapeutics EBITDA Estimates
Atara Biotherapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $20.34M N/A | $63.57M 212.55% | $8.57M -86.51% | Avg: $71.46M Low: $39.14M High: $103.78M avg. 733.62% | Avg: $94.26M Low: $65.17M High: $132.26M avg. 31.89% | Avg: $224.16M Low: $154.98M High: $314.54M avg. 137.80% | Avg: $150M Low: $103.71M High: $210.47M avg. -33.08% |
Net Income
% change YoY
| $-340.14M N/A | $-228.30M 32.88% | $-276.12M -20.94% | Avg: $-119.04M Low: $-3.30B High: $-1.45B avg. 56.88% | Avg: $-92.73M Low: $-2.75B High: $-1.19B avg. 22.09% | Avg: $79.43M Low: $47.56M High: $121.06M avg. 185.65% | Avg: $-397.17M Low: $-605.34M High: $-237.84M avg. -600.00% |
EBITDA
% change YoY
| $-340.46M N/A | $-330.75M 2.85% | $-265.99M 19.57% | Avg: $-14.29M Low: $-20.75M High: $-7.82M avg. 94.62% | Avg: $-18.85M Low: $-26.45M High: $-13.03M avg. -31.89% | Avg: $-44.83M Low: $-62.90M High: $-30.99M avg. -137.80% | Avg: $-29.99M Low: $-42.09M High: $-20.74M avg. 33.08% |
EPS
% change YoY
| -$3.63 N/A | -$2.24 38.29% | -$65.18 -2809.82% | Avg: -$21.56 Low: -$31.25 High: -$13.75 avg. 66.91% | Avg: -$18.63 Low: -$26 High: -$11.25 avg. 13.62% | Avg: $0.75 Low: $0.45 High: $1.14 avg. 104.02% | Avg: -$3.75 Low: -$5.72 High: -$2.25 avg. -600% |
Operating Expenses
% change YoY
| $360.80M N/A | $344.08M -4.63% | $275.69M -19.87% | Avg: $183.07M Low: $100.27M High: $265.86M avg. -33.59% | Avg: $241.46M Low: $166.95M High: $338.82M avg. 31.89% | Avg: $574.22M Low: $397.02M High: $805.74M avg. 137.80% | Avg: $384.24M Low: $265.67M High: $539.17M avg. -33.08% |
FAQ
What is Atara Biotherapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -83.83% in 2025-2028.
We have gathered data from 4 analysts. Their low estimate is -3.30B, average is -119.04M and high is -1.45B.
What is Atara Biotherapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 217.56% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is $39.14M, average is $71.46M and high is $103.78M.
What is Atara Biotherapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -103.85% in 2025-2028.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$31.25, average is -$21.56 and high is $-13.75.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Atara Biotherapeutics stock. The most successful analyst is Benjamin Burnett.